An observational study in Signs and Symptoms, Fever and Myalgia, sponsored by OpenGenome. Recruiting at 1 site in Germany. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-19.
Sponsored by OpenGenome · Observational
This registry prospectively collects anonymized free-text symptom descriptions submitted voluntarily by adults through the OpenGenome platform at opengenome.bio. For each submission, the system retrieves real biomedical literature from PubMed and ClinicalTrials.gov in parallel, applies a constrained reasoning model operating under a strict output schema, and returns a structured biological signal report. The study evaluates the internal consistency of extracted signals, the calibration of confidence scores relative to dataset size and symptom specificity, and the distribution of biological signal categories across a large anonymous population. No intervention is assigned. No participant contact occurs. All data is anonymized at the point of collection.
OpenGenome is a publicly accessible, anonymous research instrument that maps free-text symptom descriptions to structured biological signals grounded in primary biomedical literature. Upon submission, the platform dispatches parallel queries to PubMed via NCBI E-utilities and ClinicalTrials.gov v2 API, retrieving up to 16 real sources per submission. A reasoning model constrained by a strict schema extracts a primary biological signal, up to five secondary signals, a plain-language correlation explanation, a confidence score, and a signal strength score. All scores are integers on a 0 to 100 scale. Sources are included by PMID or NCT identifier and are directly linkable for independent verification. This registry will analyze aggregate anonymized outputs to characterize signal consistency, score calibration, and population-level signal distributions.
221 studies on the registry are indexed under Signs and Symptoms; 22 are open to participants now.
This study's planned enrollment of 1,000 is above the median of 189 across 58 observational studies indexed under Signs and Symptoms.
Browse Signs and Symptoms studies →This is the only study on the registry with OpenGenome as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Adults aged 18 years or older who voluntarily access the OpenGenome platform at opengenome.bio and submit a free-text description of symptoms or health-related observations for automated biomedical signal analysis.
Adults aged 18 or older who voluntarily submit a free-text symptom description via the OpenGenome platform and receive a structured biological signal report. No intervention is assigned.
Other: OpenGenome AI Platform
AI-assisted biomedical signal extraction from free-text symptom descriptions, cross-referenced against PubMed and ClinicalTrials.gov evidence sources.
Internal signal-source concordance rate
Proportion of primary signal claims in generated reports that are traceable to at least one retrieved PubMed or ClinicalTrials.gov source included in the same report
Time frame: At point of automated report generation, assessed continuously over 12 months
Plan to share: No — Individual participant data is not available as all submissions are fully anonymous with no participant identifiers collected. Aggregate deidentified summary statistics will be made available upon study completion.
No publications or documents are linked to this record.
Started May 2026 (actual). Primary completion is estimated for May 2028, 24 months after the start.
Of 20 observational studies under Signs and Symptoms, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 20. This study's planned 24 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.